340B Clinical Insights

Clinical Insights: July 12, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Leqembi®(lecanemab-irmb) Injection – New Expanded Label – July 12, 2023 – The U.S. Food and Drug Administration converted Leqembi®(lecanemab-irmb), indicated to treat adult…

Read More...

Clinical Insights: July 5, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Roctavian™ (valoctocogene roxaparvovec-rvox) Suspension for Intravenous Infusion – New Orphan Drug Approval – June 29, 2023 – The U.S. Food and Drug Administration approved Roctavian™, an adeno-associated virus vector-based…

Read More...

Clinical Insights: June 28, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Litfulo™ (ritlecitinib) – New Drug Approval – June 23, 2023 – Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved Litfulo™ (ritlecitinib), a…

Read More...

Clinical Insights: June 21, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Columvi® (glofitamab-gxbm) Injection – New Drug Approval – June 15, 2023 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and…

Read More...

Clinical Insights: June 14, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Linzess® (linaclotide) Capsules – New Label Expansion – June 12, 2023 – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today…

Read More...

Clinical Insights: June 7, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Abrysvo™ (respiratory syncytial virus vaccine) Injection – New Drug Approval – May 31, 2023 – Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has…

Read More...

Clinical Insights: June 1, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Inpefa™ (sotagliflozin) – New Drug Approval ­– May 26, 2023 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that the U.S. Food and Drug Administration (FDA) has approved Inpefa™ (sotagliflozin),…

Read More...

Clinical Insights: May 24, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Opvee® (nalmefene hydrochloride) Nasal Spray – New Drug Approval – May 22, 2023 – The U.S. Food and Drug Administration approved Opvee®, the first nalmefene hydrochloride nasal spray for the…

Read More...

Clinical Insights: May 17, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Veozah™ (fezolinetant) – New Drug Approval – May 12, 2023 – The U.S. Food and Drug Administration approved Veozah™ (fezolinetant), an oral medication for the treatment of moderate to…

Read More...

Clinical Insights: May 10, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Mydcombi™ (phenylephrine hydrochloride and tropicamide) Ophthalmic Spray – New Drug Approval ­– May 5, 2023 –  Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing the Optejet® device for…

Read More...

Clinical Insights: May 3, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Lumryz™ (sodium oxybate) – formerly FT218 – New Drug Approval – May 1, 2023 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform…

Read More...

Clinical Insights: April 26, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Polivy® (polatuzumab vedotin-piiq) – New Label Expansion ­– April 19, 2023 – The Food and Drug Administration approved polatuzumab vedotin-piiq (Polivy®, Genentech, Inc.)…

Read More...